• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Heron Therapeutics Inc. (Amendment)

    2/6/24 11:43:22 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRTX alert in real time by email
    SC 13G/A 1 hero23a13.htm hero23a13.htm - Generated by SEC Publisher for SEC Filing  

     

              CUSIP NO. 427746102                    13G                               Page 1 of 13

     

     

                                                                                       UNITED STATES

                                                                  SECURITIES AND EXCHANGE COMMISSION

                                                                              Washington, D.C. 20549

     

                                                                                        SCHEDULE 13G

     

                                                           Under the Securities Exchange Act of 1934

                                                                                 (Amendment No. 13)*

     

                                                                            HERON THERAPEUTICS, INC.

                                                                                    (Name of Issuer)

     

                                                             Common Stock, par value $0.01 per share

                                                                      (Title of Class of Securities)

     

                                                                                           427746102

     

                                                                                      (CUSIP Number)

     

                                                                                   December 31, 2023

                                             (Date of Event Which Requires Filing of this Statement)

     

              Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

              [X] Rule 13d‑1(b)

              [ ] Rule 13d‑1(c)

              [ ] Rule 13d‑1(d)

     

              *The remainder of this cover page shall be filled out for a reporting person's initial

              filing on this form with respect to the subject class of securities, and for any

              subsequent amendment containing information which would alter the disclosures provided in

              a prior cover page.

     

              The information required in the remainder of this cover page shall not be deemed to be

              "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or

              otherwise subject to the liabilities of that section of the Act but shall be subject to

              all other provisions of the Act (however, see the Notes).

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 2 of 13

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Resources, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          Delaware

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.     SOLE VOTING POWER

     

                                       (See Item 4)

                          6.     SHARED VOTING POWER

     

                                       (See Item 4)

                          7.     SOLE DISPOSITIVE POWER

     

                                       (See Item 4)

                          8.     SHARED DISPOSITIVE POWER

     

                                       (See Item 4)

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                           6,404,795

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                           CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                           4.3%

     

              12.   TYPE OF REPORTING PERSON

     

                           HC, CO (See Item 4)

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 3 of 13

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Charles B. Johnson1

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                      (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                      (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          (See Item 4)6,404,795

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          (See Item 4)

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


    1 shares of common stock of Franklin Resources, Inc. held in a revocable trust for which Mr. C.B. Johnson is trustee, as well as shares held in 401(k) Plan, shares held in an individual retirement account, and shares held by three private charitable foundations for which he is a trustee with shared voting and investment power (Mr. C.B. Johnson disclaims beneficial ownership of such shares).

     

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 4 of 13

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Rupert H. Johnson, Jr.2

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                      (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                      (See Item 4)

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          (See Item 4)

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          (See Item 4)

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


    2 shares of common stock of Franklin Resources, Inc. held in a revocable trust for which Mr. R. H. Johnson, Jr. is trustee, as well as shares held in 401(k) Plan, shares held in an individual retirement account, shares held by his spouse (Mr. R. H. Johnson, Jr. disclaims beneficial ownership of such shares), and shares held by a private charitable foundation for which he is a trustee (Mr. R. H. Johnson, Jr. disclaims beneficial ownership of such shares).

     

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 5 of 13

     

     

              Item 1.

     

              (a)   Name of Issuer

     

               HERON THERAPEUTICS, INC.

     

              (b)   Address of Issuer's Principal Executive Offices

     

               4242 Campus Point Court, Suite 200

               San Diego, CA 92121

     

              Item 2.

     

              (a)   Name of Person Filing

     

                          (i):   Franklin Resources, Inc.

     

                          (ii):  Charles B. Johnson

     

                          (iii): Rupert H. Johnson, Jr.

     

     

              (b)   Address of Principal Business Office or, if none, Residence

     

                          (i), (ii), and (iii):

                          One Franklin Parkway

                          San Mateo, CA 94403‑1906

     

              (c)   Citizenship

     

                          (i): Delaware

                          (ii) and (iii): USA

     

              (d)   Title of Class of Securities

     

               Common Stock, par value $0.01 per share

     

     

              (e)   CUSIP Number

     

                          427746102

     

     


     
     

              CUSIP NO. 427746102                    13G                               Page 6 of 13

     

     

              Item 3.   If this statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c),

                                  check whether the person filing is a:

     

                            (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

                            (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

                            (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

                            (d) [ ] Investment company registered under section 8 of the Investment Company Act

                                            of 1940 (15 U.S.C 80a‑8).

     

                            (e) [ ] An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);

     

                            (f) [ ] An employee benefit plan or endowment fund in accordance with §240.13d‑1(b)

                                            (1)(ii)(F);

     

                            (g) [X] A parent holding company or control person in accordance with §240.13d‑1(b)

                                            (1)(ii)(G);

     

                            (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit

                                            Insurance Act (12 U.S.C. 1813);

     

                            (i) [ ] A church plan that is excluded from the definition of an investment company

                                            under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.

                                            80a‑3);

                            (j) [ ] A non‑U.S. institution in accordance with §240.13d‑1(b)(ii)(J);

     

                            (k) [ ] Group, in accordance with §240.13d‑1(b)(1)(ii)(K).

     

                            If filing as a non‑U.S. institution in accordance with §240.13d‑1(b)(1)(ii)(J),

                            please specify the type of institution:

            Item 4.   Ownership

     

            The securities reported herein are beneficially owned by one or more open or closed end

            investment companies or other managed accounts that are investment management clients of

            investment managers that are direct and indirect subsidiaries (each, an “Investment

            Management Subsidiary” and, collectively, the “Investment Management Subsidiaries”) of

            Franklin Resources Inc. (“FRI”), including the Investment Management Subsidiaries listed

            in this Item 4.  When an investment management contract (including a sub advisory

            agreement) delegates to an Investment Management Subsidiary investment discretion or

            voting power over the securities held in the investment advisory accounts that are

            subject to that agreement, FRI treats the Investment Management Subsidiary as having sole

            investment discretion or voting authority, as the case may be, unless the agreement

            specifies otherwise. Accordingly, each Investment Management Subsidiary reports on

            Schedule 13G that it has sole investment discretion and voting authority over the

            securities covered by any such investment management agreement, unless otherwise noted in

            this Item 4.  As a result, for purposes of Rule 13d‑3 under the Act, the Investment

            Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners

            of the securities reported in this Schedule 13G.

     

            Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is

            being reported in conformity with the guidelines articulated by the SEC staff in Release

            No. 34‑39538 (January 12, 1998) (the “1998 Release”) relating to organizations, such as

            FRI, where related entities exercise voting and investment powers over the securities

            being reported independently from each other. The voting and investment powers held by

            each of FRI’s affiliates whose ownership of securities is disaggregated from that of FRI

            in accordance with the 1998 Release (“FRI Disaggregated Affiliates”) are exercised

            independently from FRI and from all other Investment Management Subsidiaries (FRI, its

            affiliates and the Investment Management Subsidiaries other than FRI Disaggregated

            Affiliates are collectively, “FRI Aggregated Affiliates”). Furthermore, internal policies

            and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand,

            FRI establish informational barriers that prevent the flow among, on the one hand, FRI

            Disaggregated Affiliates (including preventing the flow between such entities), and, on

     

     


     
     

              CUSIP NO. 427746102                    13G                               Page 7 of 13

     

     

              the other hand, the FRI Aggregated Affiliates of information that relates to the voting

              and investment powers over the securities owned by their respective investment management

              clients. Consequently, FRI Disaggregated Affiliates report the securities over which they

              hold investment and voting power separately from the FRI Aggregated Affiliates for

              purposes of Section 13 of the Act.

     

              Charles B. Johnson and Rupert H. Johnson, Jr. (the “Principal Shareholders”) each own in

              excess of 10% of the outstanding common stock of FRI and are the principal stockholders

              of FRI.  FRI and the Principal Shareholders may be deemed to be, for purposes of Rule

              13d‑3 under the Act, the beneficial owners of securities held by persons and entities for

              whom or for which FRI subsidiaries provide investment management services.  The number of

              shares that may be deemed to be beneficially owned and the percentage of the class of

              which such shares are a part are reported in Items 9 and 11 of the cover pages for FRI

              and each of the Principal Shareholders.  FRI, the Principal Shareholders and each of the

              Investment Management Subsidiaries disclaim any pecuniary interest in any of such

              securities.  In addition, the filing of this Schedule 13G on behalf of the Principal

              Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be

              construed as an admission that any of them is, and each of them disclaims that it is, the

              beneficial owner, as defined in Rule 13d‑3, of any of the securities reported in this

              Schedule 13G.

     

              FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries

              believe that they are not a “group” within the meaning of Rule 13d‑5 under the Act and

              that they are not otherwise required to attribute to each other the beneficial ownership

              of the securities held by any of them or by any persons or entities for whom or for which

              the Investment Management Subsidiaries provide investment management services.

     

     

                          (a)    Amount beneficially owned:

     

                                       6,404,795

     

                          (b)    Percent of class:

     

                                        4.3%

     

                          (c)    Number of shares as to which the person has:

     

                                  (i)   Sole power to vote or to direct the vote

     

                                                Franklin Resources, Inc.:                                        0

     

                                                Charles B. Johnson:                                              0

     

                                                Rupert H. Johnson, Jr.:                                          0

     

     

                                                Franklin Advisers, Inc.:                                 6,354,365

     

                                                Fiduciary Trust Company International:                      49,330

     

     

                                (ii)   Shared power to vote or to direct the vote                            0

     

                              (iii)   Sole power to dispose or to direct the disposition of

     

                                              Franklin Resources, Inc.:                                         0

     

                                              Charles B. Johnson:                                               0

     

                                              Rupert H. Johnson, Jr.:                                           0

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 8 of 13

     

                                              Franklin Advisers, Inc.:                                  6,355,465

     

                                              Fiduciary Trust Company International:                       49,330

     

                                (iv)   Shared power to dispose or to direct the disposition of                  0

     

              Item 5.  Ownership of Five Percent or Less of a Class

     

                                If this statement is being filed to report the fact that as of the date hereof

                                the reporting person has ceased to be the beneficial owner of more than five

                                percent of the class of securities, check the following [X].

     

              Item 6.  Ownership of More than Five Percent on Behalf of Another Person

     

                                The clients of the Investment Management Subsidiaries, including investment

                                companies registered under the Investment Company Act of 1940 and other

                                managed accounts, have the right to receive or power to direct the receipt of

                                dividends from, and the proceeds from the sale of, the securities reported

                                herein.

     

              Item 7.  Identification and Classification of the Subsidiary Which Acquired the

                                Security Being Reported on By the Parent Holding Company

     

                                See Attached Exhibit C

     

              Item 8.  Identification and Classification of Members of the Group

     

                                Not Applicable

              Item 9.  Notice of Dissolution of Group

     

                                Not Applicable

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 9 of 13

     

     

              Item 10. Certification

     

              By signing below I certify that, to the best of my knowledge and belief, the

              securities referred to above were acquired and are held in the ordinary course of

              business and were not acquired and are not held for the purpose of or with the

              effect of changing or influencing the control of the issuer of the securities and

              were not acquired and are not held in connection with or as a participant in any

              transaction having that purpose or effect, other than activities solely in

              connection with a nomination under § 240.14a‑11.

     

              Exhibits:

              Exhibit A ‑ Joint Filing Agreement

              Exhibit B ‑ Limited Powers of Attorney for Section 13 Reporting Obligations

              Exhibit C ‑ Item 7 Identification and Classification of Subsidiaries

     

                                                                                      SIGNATURE

     

              After reasonable inquiry and to the best of my knowledge and belief, I certify that

              the information set forth in this statement is true, complete and correct.

     

              Dated:   January 22, 2024

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

     

     

              By:    /s/VIRGINIA ROSAS

                            ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

     

                            Virginia Rosas

                            Assistant Secretary of Franklin Resources, Inc.

     

                            Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                            attached to this Schedule 13G

     

                            Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                            attached to this Schedule 13G

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 10 of 13

     

              EXHIBIT A

     

              JOINT FILING AGREEMENT

     

              In accordance with Rule 13d‑1(k) under the Securities Exchange Act of 1934, as amended,

              the undersigned hereby agree to the joint filing with each other of the attached

              statement on Schedule 13G and to all amendments to such statement and that such

              statement and all amendments to such statement are made on behalf of each of them.

     

              IN WITNESS WHEREOF, the undersigned have executed this agreement on  January 22, 2024.

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

     

     

              By:     /s/VIRGINIA ROSAS

                              ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

     

                              Virginia Rosas

                              Assistant Secretary of Franklin Resources, Inc.

     

                              Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                              attached to this Schedule 13G

     

                              Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                              attached to this Schedule 13G

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 11 of 13

     

     

                                                                                            EXHIBIT B

                                                                                 LIMITED POWER OF ATTORNEY

                                                          FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

              Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

         The undersigned acknowledges that:

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023.

     

                                                        /s/CHARLES B. JOHNSON

                                                        Signature

                                                        Charles B. Johnson

                                                        Print Name

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 12 of 13

     

     

                                                                            LIMITED POWER OF ATTORNEY

                                                          FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

              Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

         The undersigned acknowledges that:

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023.

     

                                                        /s/RUPERT H. JOHNSON, JR.

                                                        Signature

                                                        Rupert H. Johnson, Jr.

                                                        Print Name

     

     


     
     

     

              CUSIP NO. 427746102                    13G                               Page 13 of 13

     

     

              EXHIBIT C

     

              Franklin Advisers, Inc.                                    Item 3 Classification: 3(e)

         Fiduciary Trust Company International                      Item 3 Classification: 3(b)

     

     

     

    Get the next $HRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HRTX

    DatePrice TargetRatingAnalyst
    6/13/2024$7.00Buy
    Rodman & Renshaw
    4/23/2024$6.00Overweight
    CapitalOne
    3/13/2024$4.00 → $5.00Buy
    Needham
    More analyst ratings

    $HRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

      Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the firs

      5/6/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

      — Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI® (aprepitant) injectable emulsion and APONVIE® (aprepitant) injectable emulsion. Pursuant to the terms of the settlement agreement, the Company has granted Mylan a license under

      5/6/25 7:30:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

      CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

      4/28/25 6:55:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Heron Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $7.00

      6/13/24 7:14:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Heron Therapeutics with a new price target

      CapitalOne initiated coverage of Heron Therapeutics with a rating of Overweight and set a new price target of $6.00

      4/23/24 6:55:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Heron Therapeutics with a new price target

      Needham reiterated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $5.00 from $4.00 previously

      3/13/24 7:55:22 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

      11/22/24 4:36:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for APONVIE issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

      3/11/24 4:38:31 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for CINVANTI issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

      3/11/24 4:38:29 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Hensley Mark Earl

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/7/25 12:20:50 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Development Officer Forbes William P converted options into 11,694 shares, increasing direct ownership by 11% to 122,566 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/2/25 8:41:15 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Financial Officer Duarte Ira converted options into 11,694 shares, increasing direct ownership by 9% to 136,149 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/2/25 8:32:09 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Financials

    Live finance-specific insights

    See more
    • Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

      Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the firs

      5/6/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

      CARY, N.C., April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Invest

      4/22/25 4:05:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

      Achieved Q4 2024 GAAP Net Income of $3.6 millionGenerated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-yearDelivered full-year 2024 adjusted EBITDA of $8.6 millionGenerated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA, LLC, and upheld the validity of CINVANTI® patents which expire in 2035 CARY, N.C., Feb. 27, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 3

      2/27/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    SEC Filings

    See more
    • SEC Form S-8 filed by Heron Therapeutics Inc.

      S-8 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 5:00:45 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Heron Therapeutics Inc.

      10-Q - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 7:45:21 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 7:45:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Forbes William P bought $27,250 worth of shares (25,000 units at $1.09), increasing direct ownership by 46% to 79,000 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/21/23 12:19:26 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forbes William P bought $46,995 worth of shares (50,000 units at $0.94), increasing direct ownership by 1,250% to 54,000 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/20/23 10:07:28 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collard Craig A bought $137,970 worth of shares (150,000 units at $0.92), increasing direct ownership by 411% to 186,496 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/17/23 12:37:52 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

      CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

      4/28/25 6:55:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

      SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera

      11/4/24 5:00:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

      SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth. "Now is the right time to add substantial BD and M&A experience to the management team at Heron, and I welcome Brett to

      9/3/24 8:00:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Heron Therapeutics Inc.

      SC 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      11/12/24 9:32:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Heron Therapeutics Inc. (Amendment)

      SC 13D/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      5/31/24 11:08:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Heron Therapeutics Inc. (Amendment)

      SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      2/14/24 4:37:34 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care